Published in J Infect Dis on March 01, 2000
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol (2008) 2.88
2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med (2014) 2.22
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem (2009) 1.37
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses (2010) 1.24
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother (2004) 1.12
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 1.10
Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol (2003) 1.09
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2003) 1.06
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One (2011) 1.04
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol (2006) 1.01
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One (2011) 0.95
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr Opin Virol (2013) 0.95
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother (2002) 0.90
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology (2013) 0.90
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother (2004) 0.88
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance. Viruses (2010) 0.85
The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance. Viruses (2014) 0.83
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother (2009) 0.80
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations. Antimicrob Agents Chemother (2013) 0.79
Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. Antiviral Res (2014) 0.78
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Antimicrob Agents Chemother (2009) 0.78
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication. J Virol (2014) 0.78
D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance. J Med Chem (2007) 0.78
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (2006) 0.76
Synthesis and Inhibiting Activity of Some 4-Hydroxycoumarin Derivatives on HIV-1 Protease. ISRN Pharm (2011) 0.75
Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications? Eur J Med Res (2010) 0.75
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol (2004) 4.28
Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature (2000) 3.69
Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology (2000) 3.15
Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology (1978) 3.08
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol (1999) 2.51
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Characterization of a cancer cachectic factor. Nature (1996) 2.46
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg (1991) 2.42
The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol (1989) 2.40
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med (1996) 2.32
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science (1999) 2.21
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15
Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Genes Dev (1995) 2.13
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03
Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem (2000) 1.97
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85
Yield of combined perfusion and diffusion MR imaging in hemispheric TIA. Neurology (2008) 1.80
Internet is useful for information on rare conditions. BMJ (1997) 1.76
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother (2000) 1.75
Screening for lung cancer. Cochrane Database Syst Rev (2004) 1.71
An in vitro model of angiogenesis: basic features. Angiogenesis (1999) 1.71
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr (2001) 1.71
4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature (1981) 1.69
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis (1998) 1.67
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Thymineless death in Bacillus megaterium. J Bacteriol (1964) 1.61
Mapping of quantitative trait loci controlling trypanotolerance in a cross of tolerant West African N'Dama and susceptible East African Boran cattle. Proc Natl Acad Sci U S A (2003) 1.60
Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol (2000) 1.59
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res (1996) 1.56
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS (2000) 1.53
Volume of isoflow. A new test in detection of mild abnormalities of lung mechanics. Am Rev Respir Dis (1974) 1.53
Nationwide outbreak of listeriosis due to contaminated meat. Epidemiol Infect (2005) 1.52
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science (1995) 1.48
Small bakeries--a cross-sectional study of respiratory symptoms, sensitization and dust exposure. Occup Med (Lond) (1999) 1.44
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 1.43
HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses (2000) 1.41
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem (1996) 1.39
Comparative effects of 5-fluorouracil on strains of Bacillus megaterium. J Bacteriol (1964) 1.39
HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. Biochemistry (1988) 1.38
New polymorphic microsatellite markers place the haemochromatosis gene telomeric to D6S105. Hum Mol Genet (1995) 1.38
Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol (1989) 1.33
Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol (1998) 1.32
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29
N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem (1993) 1.28
Connexin32 gene mutations in X-linked dominant Charcot-Marie-Tooth disease (CMTX1). Hum Genet (1997) 1.26
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis (1998) 1.26
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A (2001) 1.26
Rapid purification and characterisation of HIV-1 reverse transcriptase and RNaseH engineered to incorporate a C-terminal tripeptide alpha-tubulin epitope. FEBS Lett (1991) 1.26
Peroxisomes, lipid metabolism and lipotoxicity. Biochim Biophys Acta (2010) 1.25
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS (2000) 1.23
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 1.22
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids (2001) 1.19
Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet (1993) 1.17
Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes (2001) 1.16
Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. Virus Res (1999) 1.14
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther (2001) 1.14
Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein. Am J Hum Genet (1995) 1.13
In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology (1999) 1.13
A specialized crisis response site as a core element of police-based diversion programs. Psychiatr Serv (2001) 1.12
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS (2000) 1.10
Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. J Biol Chem (1993) 1.10
X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res (1999) 1.09
Exercise induced leg pain. Br J Sports Med (1997) 1.08
Stability of normal personality traits after traumatic brain injury. J Head Trauma Rehabil (1998) 1.08
Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1. Biochemistry (2000) 1.07
Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother (1994) 1.07
Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology (2005) 1.07
The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res (1996) 1.06
Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol (1999) 1.06
Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res (2008) 1.04
Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology (2000) 1.03
Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Res Hum Retroviruses (1996) 1.03
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses (2000) 1.02
What happens if you retest autobiographical memory 10 years on? Mem Cognit (2001) 1.02
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther (2000) 1.01
L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem (1999) 1.01
Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother (1984) 1.01
Single sweetness signal. Nature (1994) 1.01